Entropy Technologies LP Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Entropy Technologies LP bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,100 shares of the biopharmaceutical company’s stock, valued at approximately $359,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Atlantic Union Bankshares Corp acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $30,000. SVB Wealth LLC purchased a new stake in Alnylam Pharmaceuticals in the first quarter valued at $27,000. Ameritas Advisory Services LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $42,000. AlphaQuest LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $43,000. Finally, Parkside Financial Bank & Trust increased its position in shares of Alnylam Pharmaceuticals by 32.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 44 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ:ALNY opened at $429.80 on Wednesday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The firm’s 50 day moving average price is $456.13 and its 200 day moving average price is $393.87. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The stock has a market cap of $56.78 billion, a price-to-earnings ratio of -174.01 and a beta of 0.30.

Insiders Place Their Bets

In related news, EVP Pushkal Garg sold 3,022 shares of the stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the transaction, the executive vice president owned 20,221 shares of the company’s stock, valued at $9,129,377.08. This represents a 13.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the sale, the executive vice president directly owned 21,264 shares of the company’s stock, valued at $9,615,155.52. This trade represents a 36.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 78,328 shares of company stock worth $35,705,793. 1.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ALNY shares. Bank of America increased their price objective on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Royal Bank Of Canada lifted their price objective on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a research note on Friday, September 19th. Chardan Capital boosted their price objective on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a report on Friday, August 1st. Wolfe Research upgraded Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a report on Monday, August 4th. Finally, Evercore ISI boosted their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. Twenty-three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $482.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.